

PC929: Applied Pharmacology and Therapeutics in Diabetes Care

[View Online](#)

1.

The Scottish Intercollegiate Guidelines Network website is at <http://www.sign.ac.uk>.
<http://www.sign.ac.uk/>

2.

The American Diabetes Association. <https://www.diabetes.org/>

3.

The Cochrane collaboration at <http://www.cochrane.org/> helps "healthcare practitioners, policy-makers, patients, their advocates and carers make well-informed decisions about health care, by preparing, updating, and promoting the accessibility of Cochrane Reviews.". <http://www.cochrane.org/>

4.

NHS Evidence, an offshoot of NICE, provides basic information on evidence-based management of many common conditions, including diabetes, and can be found at <https://www.evidence.nhs.uk/>. <https://www.evidence.nhs.uk/>

5.

The commercial but not-for-profit Trip database at <http://www.tripdatabase.com> claims to be "the internet's premier source of evidence-based content".
<http://www.tripdatabase.com/>

6.

The International Diabetes Federation (IDF) is at <http://www.idf.org>. <http://www.idf.org/>

7.

The George Eliot Diabetes Care Team's Alphabet Strategy website is at www.abcdiabetes.co.uk. <http://www.abcdiabetes.co.uk/>

8.

The Critical Appraisal Skills Programme (CASP) critical appraisal checklists can be downloaded from <http://www.casp-uk.net/>. <https://casp-uk.net/casp-tools-checklists/>

9.

Essential Values-Based Practice is supported by a website jointly hosted by Cambridge University Press and Warwick Medical School at <http://www.go.warwick.ac.uk/values-basedpractice>. <http://valuesbasedpractice.org/>

10.

The European Association for the Study of Diabetes (EASD). <http://www.easd.org/>

11.

Diabetes Care: 40 (Supplement 1). Diabetes Care. 2017;40(Supplement 1).
https://0-care-diabetesjournals-org.pugwash.lib.warwick.ac.uk/content/40/Supplement_1

12.

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720

13.

Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. *New England Journal of Medicine*. 2017;376(23):2300-2302.
<http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMc1701990>

14.

Effects of Liraglutide on Glycemic Control :*Cleveland Clinic Journal of Medicine*. Published online 2015.
<http://www.mdedge.com/ccjm/clinical-edge/summary/obesity/effects-liraglutide-glycemic-control>

15.

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New England Journal of Medicine*. 2017;(377):644-657.
<http://0-www.nejm.org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1611925#t=article>

16.

Nauck MA. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks. *Diabetes Care*. 2013;36(7):2126-2132.
doi:10.2337/dc12-2504

17.

Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 2013;369(14):1317-1326. doi:10.1056/NEJMoa1307684

18.

Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient. *JAMA*. 2016;315(10). doi:10.1001/jama.2016.0299

19.

Caverly TJ, Fagerlin A, Zikmund-Fisher BJ, et al. Appropriate Prescribing for Patients With Diabetes at High Risk for Hypoglycemia. *JAMA Internal Medicine*. Published online 26

October 2015. doi:10.1001/jamainternmed.2015.5950

20.

Sinclair AJ, Bode B, Harris S, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. *Journal of the American Geriatrics Society*. 2016;64(3):543-552. doi:10.1111/jgs.14028

21.

Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. *The Lancet Diabetes & Endocrinology*. 2015;3(7):503-504.
<http://0-www.sciencedirect.com.pugwash.lib.warwick.ac.uk/science/article/pii/S2213858715002260?via%3Dihub>

22.

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(4):323-334.
doi:10.1056/NEJMoa1515920

23.

Scheen AJ. SGLT2 Inhibitors: Benefit/Risk Balance. *Current Diabetes Reports*. 2016;16(10).
doi:10.1007/s11892-016-0789-4

24.

Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovascular Diabetology*. 2015;14(1). doi:10.1186/s12933-015-0260-x

25.

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *The Lancet*. Published online December 2015. doi:10.1016/S0140-6736(15)01225-8

26.

Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. *Diabetes and Vascular Disease Research*. 2015;12(2):90-100. doi:10.1177/1479164114559852

27.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141

28.

Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. *Expert Opinion on Pharmacotherapy*. 2016;17(12):1581-1583.
<http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073>

29.

Dauriz M, Targher G, Laroche C, et al. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. *Diabetes Care*. 2017;40(5):671-678. doi:10.2337/dc16-2016

30.

Wu JHY, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. *The Lancet Diabetes & Endocrinology*. 2016;4(5):411-419. doi:10.1016/S2213-8587(16)00052-8

31.

Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. *Expert Opinion on Pharmacotherapy*. 2016;17(12):1581-1583.
<http://0-www.tandfonline.com.pugwash.lib.warwick.ac.uk/doi/full/10.1080/14656566.2016.1201073>

32.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141

33.

Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. *Annals of Internal Medicine*. 2016;164(11). doi:10.7326/M15-2650

34.

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720

35.

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *New England Journal of Medicine*. 2015;373(23):2247-2257. <https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/2119957013/EA851E49618490DPQ/1?accountid=14888>

36.

Kosiborod M, Cavender MA, Fu AZ, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective. *Circulation*. 2017;136(3):249-259. <https://0-www-ncbi-nlm-nih-gov.pugwash.lib.warwick.ac.uk/pubmed/28522450>

37.

Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. *Diabetologia*. 2018;61(1):58-65. <https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4422-0>

38.

Zeitler P, Fu J, Tandon N, et al. Type 2 diabetes in child and adolescent. *Pediatric Diabetes*. 2014;15:26-46.

<http://onlinelibrary.wiley.com/pugwash.lib.warwick.ac.uk/doi/10.1111/pedi.12179/epdf>

39.

Pediatric Diabetes. 15(S20).

<http://onlinelibrary.wiley.com/doi/10.1111/pedi.2014.15.issue-S20/issuetoc>

40.

Bangstad HJ, Danne T, Deeb L, Jarosz-Chobot P, Urakami T, Hanas R. Insulin treatment in children and adolescents with diabetes. *Pediatric Diabetes*. 2009;10(6):82-99.

doi:10.1111/j.1399-5448.2009.00578.x

41.

ABIOLA D, SATHYAPALAN T, HEPBURN D. Management of type 1 and type 2 diabetes requiring insulin. *Prescriber*. Published online 2016.

<http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/>

42.

ABIOLA D, SATHYAPALAN T, HEPBURN D. Management of type 1 and type 2 diabetes requiring insulin. *Prescriber*. Published online 2016.

<http://www.prescriber.co.uk/article/management-type-1-type-2-diabetes-requiring-insulin/>

43.

Rang H. Pharmacokinetics. In: Rang & Dale's Pharmacology. 7th ed. Elsevier/Churchill Livingstone; 2012:123-131.

<https://contentstore.cla.co.uk/secure/link?id=1d4bfbd8-c343-e611-80bd-0cc47a6bddeb>

44.

Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. *Diabetologia*. 2017;60(8):1385-1389.
<https://0-link-springer-com.pugwash.lib.warwick.ac.uk/article/10.1007/s00125-017-4301-8>

45.

Young LA, Buse JB, Weaver MA, et al. Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings. *JAMA Internal Medicine*. 2017;177(7). doi:10.1001/jamainternmed.2017.1233

46.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New England Journal of Medicine*. 2008;358(24):2545-2559.
<https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223930983?accountid=14888>

47.

Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease. *Annals of Internal Medicine*. 2017;166(3). doi:10.7326/M16-1901

48.

Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2015;373(3):232-242.
<https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1696912909?accountid=14888>

49.

Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *New England Journal of Medicine*. Published online 2017.
<https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/1931756550?accountid=>

14888

50.

Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 2013;369(14):1317-1326.
<https://0-www-nejm-org.pugwash.lib.warwick.ac.uk/doi/full/10.1056/NEJMoa1307684>

51.

Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 2008;358(6):580-591.
<https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223923658?accountid=14888>

52.

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 2015;373(22):2117-2128.
doi:10.1056/NEJMoa1504720

53.

Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia*. 2016;59(11):2298-2307.
doi:10.1007/s00125-016-4065-6

54.

The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2008;358(24):2560-2572.
<https://0-www-proquest-com.pugwash.lib.warwick.ac.uk/docview/223924651/fulltextPDF/4EC80B054DE144D4PQ/1?accountid=14888>

55.

Chen L, Pei JH, Kuang J, et al. Effect of lifestyle intervention in patients with type 2 diabetes: A meta-analysis. *Metabolism*. 2015;64(2):338-347.
[http://www.metabolismjournal.com/article/S0026-0495\(14\)00312-6/fulltext](http://www.metabolismjournal.com/article/S0026-0495(14)00312-6/fulltext)

56.

Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. *The Lancet*. 2004;363(9421):1589-1597.
<https://0-www-sciencedirect-com.pugwash.lib.warwick.ac.uk/science/article/pii/S0140673604162028>

57.

Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New England Journal of Medicine*. 2008;358(24):2545-2559. doi:10.1056/NEJMoa0802743

58.

Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *The Lancet Diabetes & Endocrinology*. 2017;5(11):887-897.
doi:10.1016/S2213-8587(17)30317-0

59.

Complications of Diabetes Mellitus | InTechOpen.
<https://www.intechopen.com/books/pathophysiology-and-complications-of-diabetes-mellitus>